全球白喉-破伤风-百日咳 (DTaP) 疫苗市场规模（按产品类型、年龄层、最终用户、区域范围）预测（至 2025 年）

白喉、破伤风和百日咳 (DTaP) 疫苗市场规模和预测

2024 年白喉-破伤风-百日咳 (DTaP) 疫苗市场规模价值 71.8 亿美元，预计到 2032 年将达到 67.5 亿美元，2026 年至 2032 年的复合年增长率为 7.3%。

• 白喉-破伤风-百日咳 (DTaP) 疫苗是一种联合疫苗，可预防三种感染疾病：白喉、破伤风和百日咳。建议所有人终生接种这些疫苗。这些疫苗通常作为儿童常规免疫计划的一部分进行接种。
• 为了保护您的孩子免受破伤风、百日咳和白喉的侵害，您应该接种DTaP疫苗。许多此类疾病可能非常严重，尤其是在幼儿中。接种疫苗是预防这些疾病的最佳方法。
• 政府疫苗接种计划、不断增强的疫苗接种意识以及疫苗技术的进步是推动 DTaP 疫苗市场发展的一些原因。
• 根据美国国家医学图书馆介绍，DTaP 疫苗是为 6 週至 6 岁之间的儿童注射的，旨在使他们获得对 DTaP 的免疫力，如果他们感染某些疫苗可预防的疾病，可能会出现致命或危及生命的併发症。

白喉-破伤风-百日咳（DTaP）疫苗的全球市场动态

影响白喉、破伤风和百日咳 (DTaP) 疫苗市场的关键市场动态是：

关键市场驱动因素

• 增加儿童疫苗接种：由于全球出生率上升以及开发中国家对儿童疫苗接种计划的兴趣增加，接种 DTaP 疫苗的儿童数量大幅增加。
• DTaP 疫苗研发活动：製药公司不断研发新的 DTaP 疫苗，包括副作用较少的疫苗和预防百日咳、破伤风、白喉和许多其他疾病的联合疫苗。
• 提高疫苗接种意识：公共卫生计画和教育宣传活动大大提高了人们对疫苗接种价值的认识，尤其是在开发中国家。越来越多的家长选择按照建议的接种时间表为孩子接种疫苗。
• 政府承诺和资源：为了使疫苗接种更加普及，一些政府已经实施并资助了强有力的免疫计划，特别是在中低收入国家。

主要挑战

• 疫苗开发成本高：开发、生产和销售一种新的 DTaP 疫苗成本高昂，这可能会阻碍公司在该领域的投资并阻碍创新。
• 错误讯息和疫苗犹豫：网路上的错误讯息和疫苗犹豫可能会导致父母推迟或拒绝为孩子接种疫苗，这可能导致避免疾病爆发并降低整体疫苗接种率。
• 供应链问题：如果製造商停止生产某些 DTaP 疫苗或遇到某些 DTaP 疫苗的生产问题，复杂的製造流程、难以获得的原材料以及复杂的分销计划可能会导致短期供不应求，从而扰乱疫苗接种计划并可能延迟儿童的保护。
• 新发病株：DTaP百日咳疫苗成分持续演化，新株的出现可能会克服疫苗的保护作用。持续研发和监测以追踪疾病流行病学的变化并适当调整疫苗配方，对于维持疫苗对新株的有效性至关重要。

主要趋势：

• 全球疫情防治：COVID-19 疫情凸显了疫情防治和疫苗接种的重要性。为了改善全球疫苗分配，提高疫苗产量，并强化疫苗供应链，各国政府、医疗体系和疫苗製造商正在加大研发和基础建设的投入。透过加强整体疫苗接种基础设施建设，并为未来可能出现的疫情做好准备，这些努力有望推动 DTaP 疫苗市场的发展。
• 人工智慧和其他先进技术：DTaP 疫苗开发越来越依赖人工智慧和其他先进技术的使用，这些技术有可能加快研究速度并增强疫苗设计和製造程序。
• 新兴市场需求不断增长：人们对一剂即可预防多种疾病的疫苗越来越感兴趣。因此，青少年整体疫苗接种需求将减少，疫苗接种完成率也会提高。五联疫苗可在DTaP的基础上增加对B肝和乙型流感的保护。
• 重视新疫苗开发：新型 DTaP 疫苗的研究和开发仍在继续，包括可能提高疗效、免疫持续时间或减少副作用的疫苗。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

4. 白喉-破伤风-百日咳 (DTaP) 疫苗市场（依产品类型）

• DTaP-IPV疫苗
• TD
• Tdap-hEPb-IPV 疫苗

5. 白喉-破伤风-百日咳 (DTaP) 疫苗市场（按年龄层）

• 成人
• 孩子们

6. 白喉-破伤风-百日咳 (DTaP) 疫苗市场（依最终用户）

• 医院
• 诊所
• 疫苗接种中心

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• GLAXOSMITHKLINE PLC（GSK）
• Sanofi Pasteur
• GlaxoSmithKline
• SERUM INSTITUTE OF INDIA PVT. LTD
• Protein Sciences Corporation
• Novartis AG
• Seqirus（formerly CSL Behring）
• Merck Sharp & Dohme Corp（MSD）
• Astellas Pharma Inc
• Pfizer Inc
• Johnson & Johnson.

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market Size And Forecast

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market size was valued at USD 7.18 Billion in 2024 and is projected to reach USD 6.75 Billion by 2032, growing at a CAGR of 7.3% from 2026 to 2032.

• The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is a combination vaccine that provides protection against three infectious diseases: diphtheria, tetanus, and pertussis (whooping cough). Even the booster shots are advised throughout life. These vaccinations are normally given to children as part of regular immunization programs.
• To protect kids from tetanus, pertussis, and diphtheria, they must receive the DTaP vaccinations. Particularly in young children, many illnesses have the potential to be serious. The best protection against these illnesses is vaccination.
• Government immunization programs, rising vaccination awareness, and developments in vaccine technology are some of the reasons driving the market for DTaP vaccines.
• According, to National Library of Medicine DTaP vaccine is injected to the 6 weeks to 6 years of age of children's it gives immunity against DTaP. People who are dependent to certain vaccine-preventable illnesses may experience fatal consequences or even life-threatening complications.

Global Diphtheria, Tetanus, and Pertussis Vaccine Market Dynamics

The key market dynamics that are shaping the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market include:

Key Market Drivers:

• Rise in Children Vaccination: The number of children receiving DTaP vaccinations is significantly rising due to rising global birth rates and increased attention on childhood immunization programs in developing nations.
• Research and Development Activities in DTaP Vaccines: Pharmaceutical companies are continually investigating and creating new and enhanced DTaP vaccines. These developments can include vaccines with fewer side effects or combination of doses that offer protection against many diseases in addition to pertussis, tetanus, and diphtheria.
• Growing Awareness Regarding Vaccinations: Public health programs and educational campaigns, especially in developing nations, are greatly raising knowledge of the value of vaccinations. More parents are choosing to vaccinate their children in accordance with suggested timelines.
• Government Initiatives and Resources: To make these vaccinations more widely available, several governments are putting in place robust immunization programs and providing financial assistance. Particularly in low- and middle-income nations is this true.

Key Challenges:

• High Cost of Vaccine Development: The process of investigating, creating, and releasing new DTaP vaccinations is costly. This may reduce the number of businesses making investments in this area could hinder innovation.
• Misinformation and Vaccine hesitation: Parents may decide to postpone or refuse to vaccinate their children as a result of misinformation spreading online and vaccine hesitation. This may lead to avoid disease outbreaks and lower immunization rates overall.
• Supply Chain Issues: Manufacturers discontinuance of some DTaP vaccinations or production problems because of things like complicated manufacturing processes, difficult to find raw materials, and complicated distribution plans might occasionally result in brief shortages of supplies. This may interfere with immunization schedules and postpone kid protection.
• Emerging Disease Strains: As pertussis, a vaccine component in the DTaP, continues to change, new strains of the disease that might overcome vaccination-induced protection are appearing. In order to maintain vaccine efficacy against developing strains, it is essential to conduct ongoing research and monitoring to track changes in disease epidemiology and modify vaccine formulations appropriately.

Key Trends:

• Worldwide Pandemic Preparedness: The COVID-19 outbreak has highlighted the significance of being ready for pandemics and having vaccinations in place. To improve global vaccine distribution networks, boost vaccine manufacturing, and strengthen vaccine supply chains, governments, healthcare systems, and vaccine manufacturers are investing in R&D and infrastructure. By strengthening the entire vaccination infrastructure and preparing for potential future epidemics, these initiatives should help the DTaP vaccine market.
• AI and Other Advanced Technologies: The development of the DTaP vaccine is increasingly reliant on the use of artificial intelligence and other advanced technologies. AI has the potential to expedite research, enhance vaccine design, and vaccine production procedures.
• Growing Demand in Emerging Markets: People are becoming more and more interested in emerging of vaccinations, which offer multi-disease protection in a single dose. As a result, a youngster requires fewer vaccinations overall, and vaccine completion rates rise. Pentavalent vaccinations, which combine DTaP with protection against Hepatitis B and Haemophilus influenza type B.
• Emphasis on Developing New Vaccines: Research and development are continuing to produce new DTaP vaccines with enhanced qualities. This covers vaccinations with increased potency, immunity that lasts longer, or reduced adverse effects.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) vaccine market:

North America:

• The duration of the forecast period, North America is anticipated to lead the market. This is explained by the fact that North America has a 34.8% market share and is home to many important industry players. Prominent industry participants, including Sanofi, AJ Vaccines A/S, GSK plc, Merck & Co., Inc., and others, are well-represented in this area.
• Due to their extensive public health awareness and well-established pediatric immunization programs, North American countries often have high vaccination rates.
• Patients in North America have greater access to DTaP vaccines because to the generally favorable reimbursement policies of both government and insurance provider providers.

Europe:

• The duration of the projection period, the Europe area is anticipated to rank second in size. Because skin conditions are becoming more common in Europe. For example, a National Library of Medicine report from March 2022 states that 185,103,774 people in Europe had a dermatological ailment or disease in 2021.
• Due to prevalence of dermatological diseases Europe contain DTaP vaccine which offers protection against bacterial illnesses such as pertussis, tetanus, and diphtheria. On the other hand, a variety of skin disorders known as dermatological illnesses are not brought on by these microorganisms.
• Numbers of European nations have firmly developed healthcare systems with strong immunization program infrastructure. European governments have implemented robust immunization policies and provided financial support, thereby facilitating the accessibility of DTaP vaccinations. These reasons contribute to the high immunization rates for DTaP vaccinations in many European nations.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market is segmented on the basis of Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Product Type

• DTaP-IPV
• TD
• Tdap-hEPb-IPV

Based on the Product Type, the market is distributed into DTaP-IPV, TD and Tdap-hEPb-IPV and Others. Due to increased DTaP vaccine usage and new product launches, the DTaP vaccine segment is anticipated to lead the diphtheria vaccine market throughout the forecast period.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Age Group

• Adult
• Pediatrics

Based on Age Group, the market is segmented into Adult and Pediatrics. During the projection period, the pediatrics category is anticipated to dominate the market, primarily because major players in the industry have increased their research and development expenditure.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By End-User

• Hospitals
• Clinics
• Vaccination Centers

Based on End-User, the market is fragmented into Hospitals, Clinics and Vaccination Centers. The course of the projection period, hospitals are anticipated to dominate the market. This is due to an increase in government measures to open hospital novel wards for the prevention of diphtheria.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is likely to remain a major player in the DTaP vaccine market in the foreseeable future, but the competitive landscape may evolve as other regions develop their markets.

Key Players

• The "Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GLAXOSMITHKLINE PLC (GSK), Sanofi Pasteur, GlaxoSmithKline, SERUM INSTITUTE OF INDIA PVT. LTD, Protein Sciences Corporation, Novartis AG, Seqirus (formerly CSL Behring), Merck Sharp & Dohme Corp (MSD), Astellas Pharma Inc, Pfizer Inc, Johnson & Johnson. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Recent Developments
• In December 2022, the 6-in-1 Hexavalent Vaccine development partnership between BIONET-ASIA, a vaccine manufacturing business, and Pharmaniaga Berhad, a pharmaceutical company based in Malaysia, was announced, with the help of the vaccine. Malaysian healthcare professionals would have the choice to vaccinate children against six common childhood illnesses, including hepatitis B (Hep-B), poliomyelitis (IPV), pertussis (aP), tetanus (TT), and diphtheria (DT).
• In June 2022 , Global pharmaceutical company GSK plc revealed that it has invested over US$ 1.2 billion to speed up research and development (R&D) aimed at creating vaccines and medications to treat and prevent HIV (through ViiV Healthcare), malaria, tuberculosis, neglected tropical diseases (NTDs), and diphtheria.
• In October 2020, a vaccine manufacturer named BIONET-ASIA declared that the Phase-II clinical trials for Tetanus, Diphtheria, and Pertussis (In Children, Prevention) were concluded in Thailand.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By Product Type

• DTaP-IPV
• TD
• Tdap-hEPb-IPV

5. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By Age Group

• Adult
• Pediatrics

6. Diphtheria, Tetanus, And Pertussis (DTaP) Vaccine Market, By End-User

• Hospitals
• Clinics
• Vaccination Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GLAXOSMITHKLINE PLC (GSK)
• Sanofi Pasteur
• GlaxoSmithKline
• SERUM INSTITUTE OF INDIA PVT. LTD
• Protein Sciences Corporation
• Novartis AG
• Seqirus (formerly CSL Behring)
• Merck Sharp & Dohme Corp (MSD)
• Astellas Pharma Inc
• Pfizer Inc
• Johnson & Johnson.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References